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A B S T R A C T
Extracellular vesicle (EV) production is a universal feature of metazoan cells as well as prokaryotes (bMVs -
bacterial microvesicles). They are small vesicles with phospholipid membrane carrying proteins, DNA and dif-
ferent classes of RNAs and are heavily involved in intercellular communication acting as vectors of information
to target cells. For the last decade, the interest in EV research has exponentially increased though thorough
studies of their roles in various pathologies that was not previously possible due to technical limitations. This
review focuses on research evaluating the role of EV production in gastrointestinal (GI) cancer development in
conjunction with GI microbiota and inﬂammatory diseases. We also discuss recent studies on the promising role
of EVs and their content as biomarkers for early diagnosis of GI cancers.
The bMVs have also been implicated in the pathogenesis of GI chronic inﬂammatory diseases, however, possible
role of bMVs in tumorigenesis remains underestimated. We propose that EVs from eukaryotic cells as well as from
diﬀerent microbial, fungi, parasitic species and edible plants in GI tract act as mediators of intracellular and inter-
species communication, particularly facilitating tumor cell survival and multi-drug resistance.
In conclusion, we suggest that matching sequences from EV proteomes (available from public databases) with
known protein sequences of microbiome gut bacteria will be useful in identiﬁcation of antigen mimicry between
evolutionary conservative protein sequences. Using this approach we identiﬁed Bacteroides spp. pseudokinase
with activation loop and homology to PDGFRα, providing a proof-of-concept strategy. We speculate that ex-
istence of microbial pseudokinase that ‘mimics’ PDGFRα may be related to PDGFRα and Bacteroides spp. roles in
colorectal carcinogenesis that require further investigation.
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1. Introduction
Chronic inﬂammation pathologies of GI such as inﬂammatory bowel
disease (IBD), Crohn's disease (CrD), Helicobacter pylori-associated in-
ﬂammation and chronic pancreatitis have been identiﬁed as strong risk
factors for cancer development [1–6]. The initial hypothesis that the
emergence of the tumor is associated with chronic inﬂammation was
postulated by Rudolf Virchow in 1863 [7]. Today, the causative link
between cancer and chronic inﬂammation is widely accepted, though
molecular and cellular mechanisms of this association have not been
resolved [8]. About 15% of the global cancer burden can be attributed
to infectious agents [9], of which chronic inﬂammation is a major
component [1]. Acute inﬂammation is self-limiting, since the produc-
tion of anti-inﬂammatory cytokines (IL-1, IL-10, IL-13 etc.) follows the
production of pro-inﬂammatory cytokines (IL-1, TNF-alpha, IFNγ etc.)
[8]. The strongest association of chronic inﬂammation and underlying
infection with cancerogenesis is found between inﬂammatory bowel
diseases and colon cancer, Helicobacter pylori and gastric cancer, he-
patitis C and liver carcinoma, schistosomiasis and bladder and colon
carcinomas [10]. The broader implication of these observations was
that chemokines and other cytokines are widely involved in cancer
development, however, the detailed mechanisms linked to infection and
inﬂammation in relation to cancer are not well understood.
It is well known that cell activation and pathogenesis of a variety of
diseases are often associated with increased levels of EVs released in
body ﬂuids including plasma, liquor, urine, bile, saliva, semen, vitreous
and synovial ﬂuids, atherosclerotic plagues, mucus and intestinal ﬂuids,
ascitic and pleural ﬂuids [11–14]. EVs production by eukaryotic cells is
upregulated during cell activation and growth, thus playing an essential
role in cellular communication during cancer development. However,
until recently it was not clear how commensal and pathogenic bacteria,
and members of gut microbiota, communicate with other microbial and
eukaryotic cells and the immune system. Studies during the last decade
that are focusing on the association between gastrointestinal cancer and
inﬂammatory diseases with certain types of bacterial infections often are
overlooking the intensive production of outer membrane vesicles (OMPs)
by diﬀerent types of gastrointestinal bacterial commensals and patho-
gens as well as fungi, parasites invading the GI tract, and nematodes.
This review focuses on research assessing EVs originating from
diﬀerent types of eukaryotic and prokaryotic cells inside the GI tract
which separates symbionts and commensals in our bodies. We also
discuss the role of EVs originated from GI cancers as potential bio-
marker tools. Early diagnosis of GI cancers continues to be a major
challenge with a miss rate of up to 6.7% - for the upper GI tract with
endoscopy and colonoscopy [15] and up to 6% miss rate for colorectal
cancers [16]. Due to the invasiveness of these procedures and the
possibility of complications [17], there is a high need for robust cir-
culating biomarkers of GI cancers and eﬀective non-invasive mon-
itoring. In conclusion, we suggest that matching sequences from EV
proteomes (available from public databases) with known protein se-
quences of microbiome gut bacteria will be useful in identiﬁcation new
molecular mimicry target protein sequences and provide a proof-of-
concept strategy identifying B. fragilis pseudokinase that ‘mimic’
PDGFRα.
2. Extracellular vesicles (EVs) structure and biogenesis
Generally, three diﬀerent classes of EVs (Fig. 1) are produced by
metazoan cells, namely, exosomes, microparticles (MPs) or micro-
vesicles, sometimes also named ectosomes, and apoptotic bodies. These
EVs are distinguished by size, their content, morphology and by dif-
ferent mechanisms of their biogenesis [18–19]. Moreover, it is well
accepted that production of EVs represents a universal feature of life,
since gram-negative and gram-positive bacteria as well as Archaea
generate outer membrane vesicles [20–24]. It is believed that the for-
mation of microparticles (MPs) usually happens via plasma membrane
budding and shedding associated with membrane sites enriched with
lipid rafts [25–26,18]. Unlike MPs, exosome formation occurs via re-
routing of multivesicular bodies (MVBs) to the cell surface [27–28],
where they fuse with the cell membrane and exit the cell through
exocytosis (detailed rev. [29]). As a result, exosomes are enriched with
endosome- and MVBs-associated proteins, such as tetraspanins (CD9,
CD63, CD81 and CD82 and CD151; whereas CD37, CD53 and Tssc6 are
restricted by hematopoietic cells) [30–31]. CD63 is important for exo-
somal secretion, as the reduction of exosomal production was observed
in CD63-knockout HEK-293 cells. However, at the same time no re-
duction in the secretion of microparticles > 150 nm size was noted,
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Fig. 1. Production of diﬀerent classes of EVs. (A)
Microparticles; (B) exosomes; (C) apoptotic
bodies; (D) outer membrane vesicles.
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secretion only [32]. Heat shock proteins HSP 70/90 are also enriched in
exosomes, but not in shedded MPs [33]. The exosomal membrane is
rigid with rigidity increasing from pH 5 to 7 as demonstrated by
membrane ﬂuidity probes (diphenylhexatriene), which is a result of
increased amounts of desaturated phosphatidylcholines (PC), phos-
phatidylethanolamine, sphingomyelin, cholesterol [34] and ceramides
[35]. Circulating exosomes are resistant to lipolytic enzymes and can
stay for up to two weeks in the lymph nodes [36]. MPs are much more
heterogeneous in size and structure, spanning from 0.1 to 1.0 μm,
whereas exosomes are typically homogenous in size (0.04–0.1 μm) and
shape [37,12]. Cells secrete exosomes and MPs simultaneously, but
their ratios diﬀer depending on the cell type and cell status [38–39].
Though their biogenesis is diﬀerent and sizes are overlapping, se-
paration and puriﬁcation of these two major classes of EVs has been
hampered by the limitations of existing methods [40–42]. Currently,
various strategies including diﬀerential ultracentrifugation, ﬁltration,
density gradient separation, immunoaﬃnity, bead puriﬁcation, and size
exclusion chromatography have been used for isolation of diﬀerent EV
fractions, however, no universal approach exists. Limitation factors for
ultracentrifugation include co-sedimentation of protein aggregates and
co-purifying of non-speciﬁcally bound proteins [40]. The most
straightforward approach for separating exosomes and MPs is FACS-
based sorting accomplished by sorting similarly sized viral particles
[43]. However, FACS-based cell sorting of EVs normally leads to size-
based selection, could also be biased by the choice of antigens selected
for FACS-sorting.
Both major EV classes contain diﬀerent protein, RNA and DNA
cargo [44–47], and also signiﬁcantly diﬀer by their lipid content. EVs
may transfer information from the host cell to various target cells by
direct cell-to-cell contact or alternatively, through secretion of soluble
mediators and eﬀectors [48–49]. Moreover, EVs may interact with
target cells via surface-bound ligands, transferred surface receptors and
membrane-associated enzymes, or deliver cytoplasmic or membrane-
associated constituents, such as cytosolic proteins, diﬀerent classes of
RNA molecules, DNA, bioactive lipids and even cellular organelles such
as mitochondria [11,14]. Several studies indicate that tumor-derived
extracellular vesicles (TEVs) harbor signaling proteins that aﬀect cell
metabolism, mRNA processing, angiogenesis, and cell growth and mo-
tility, in addition to molecules that are likely required for TEV bio-
genesis [50,28]. It has been demonstrated that at least in some cases
cellular proteins are selectively integrated into TEVs via ARF6-regu-
lated endosome recycling, where the expression and activation of ARF6
is associated with an increase of tumor-invasive potential [51,52].
Plasma membrane-derived EVs, secreted from the parent cell,
strengthens some, but not all plasma membrane proteins and those that
integrated inside EVs conserve the topology of the parent cell plasma
membrane [12].
The function of EVs appears to be dependent on their cargo. EVs
shed from various tumor-cell lines have been thought to facilitate ex-
tracellular matrix (ECM) invasion, evasion of the immune response
[53–54,37] and potentiate formation of metastasis in PDAC and other
cancers [55–57]. Shedding of tumor-derived EVs can stimulate metas-
tasis spreading, tumor-stroma interactions and angiogenesis
[55,58–62]. EVs contain complex sets of cargo, depending on the
physiological conditions in which they are generated and released, and
once shed may impact a variety of cellular processes and modulate
inﬂammatory response. The major question that remains to be eluci-
dated is how speciﬁc cargoes are selectively absorbed and accumulated
by diﬀerent classes of EVs. It has been shown that posttranslational
modiﬁcations of proteins with acyl, myristoyl, palmitoyl or glycopho-
sphatidylinositol anchors may facilitate recruitment of speciﬁc proteins
to EVs [11,63–64]. However, since recruiting of proteins happens also
in the absence of these post-translational modiﬁcations, there are other
yet unknown mechanisms that participate in protein cargo selection by
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understood, however, there are indications that uncoded regions of
RNA are involved in this process [65]. Protein and miRNA signatures
carried by EVs may represent potential biomarkers as reported by
several groups (summarized in Tables 1, 2, 3).
3. EV cargo in gastrointestinal cancer
The phenotypic and functional heterogeneity of cancer cells that
arises from heritable and stochastic epigenetic and genetic changes
increases risk of metastasizing or resistance to drug treatment, and
therefore represents one of major challenges in cancer patients treat-
ment [151–152]. Recent research in cancer heterogeneity is adding
additional layer of complexity to systemic transfer of extracellular ve-
sicles and their functional content between the cells, which can con-
tribute to tumor progression and inﬂuence anti-cancer therapies [153].
3.1. EV-associated RNA in gastrointestinal cancer
All major RNA classes are present in EVs [46]. In addition to mRNA
and miRNAs [48,154], vRNAs and yRNAs, the degraded products of
non-coding and long-coding RNAs have been found in exosomes
[155–156].
It has been shown that miRNA dysregulation is involved in the in-
itiation and progression of human cancers although the natural me-
chanism of this phenomenon is still unclear [157–158]. In normal
conditions, these small noncoding, 19 to 22 nucleotide length RNAs
participate in regulation of cellular development, diﬀerentiation, pro-
liferation, apoptosis, and cancer cell metabolism [158]. Goldie and
coauthors [159] demonstrated that exosomes contain a higher pro-
portion of miRNAs compared to other classes of small RNA. It has been
shown that exosomes are enriched with miRNA [159], certain types of
miRNA are selectively sorted to exosomes and other MPs [160].
However, the details of the mechanism of this selective sorting of
miRNAs and miRNA-associated proteins in exosomes and/or MPs are
not clear. In mammals, this process includes transcription of miRNA
genes into primary miRNAs (pri-miRNAs), and processing by the
Drosha complex to produce precursor miRNAs [161]. Pre-miRNA un-
dergoes digestion by the Dicer complex and is sorted to exosomes after
becoming mature miRNA via four potential pathways: (1) nSMase2-
dependent pathway; (2) miRISC-related pathway that is co-localized
with the sites of exosome biogenesis (MTB) and their components
(AGO2 protein and miRNA-targeted mRNA); (3) 3′ miRNA sequence
dependent pathway, and (4) miRNA motif and sumoylated hnRNPs-
dependent pathway (described in detail by [161].
Though uridylation [162] and sumoylation of miRNA [163] are
implicated in preferential sorting of miRNA in exosomes, in most cases
these targeting sequences are absent in secreted miRNAs [164].
McKenzie and co-authors [165] demonstrated using wild-type and
KRAS-mutant colon cancer cells, that KRAS-dependent activation of the
MEK-ERK pathway (mitogen-activated protein kinase kinase/extra-
cellular-signal regulated kinase) inhibits sorting of the Argonaute (Ago)
2 dependent miRNA in exosomes. There are early reports that demon-
strated the presence of Ago2, a major component of RNA-induced si-
lencing complex (RISC) as well as other proteins responsible for RNA-
processing in secreted exosomes [166–167]. Recently, another com-
ponent of RISC-complex, Y-box protein-1 has been shown to be in-
volved in sorting miRNA to CD63+ exosomes [168]. Surprisingly, the
authors did not ﬁnd evidence of Ago proteins in their isolated exosomal
preparations (CD63+ exosomes), which led them to suggest a diﬀerent
route for miRNA egress via exosomes, which they named the cha-
perone-mediated route as opposed to the Ago2-associated route.
The physiological role of EV miRNA and other cargo has been the
subject of discussion from the moment of their discovery in EVs.
Though transfer of exosomal miRNA between malignant and non-ma-
lignant cells has been proved in numerous studies [48,169–170]
(Fig. 2), the functional role of EV-associated miRNAs remains elusive.
Most of the GI cancer-related miRNA studies are based on analysis
of tissue and stool samples [171–173] and recently on plasma-derived
miRNAs [174–177].
Signiﬁcant upregulation of miRNA92a, miRNA221, miRNA29a and
miRNA17-3p compared to healthy control groups was revealed.
Furthermore, Huang and colleagues [174] showed miR-17-3p and miR-
92a to be downregulated, giving a potential biomarker for colorectal
cancer (CRC) evaluation. Huang and Yu's recent work [78] elucidated
the possible mechanism of circulating miRNAs and long non-coding
RNAs (lncRNAs) secretion for gastric cancer diagnosis and demon-
strated that circulating miRNAs and lncRNAs exhibit higher diagnostic
values relative to conventional tumor markers such as CA199, CA125,
CA724, CA242, CA50, CEA, and pepsinogen. Another group [177]
studied circulating miRNA92a carried by EVs from CRC patient's
Tumor cell Secondary recipient cell













(Toll-like receptors-MAPK; NF-kappa  )
EVs Cargo:miRNA, mRNA, lipids, proteins etc  
Angiogenesis
Fig. 2. Communication by EVs between lumen,
tumor cells and secondary recipient cells (ﬁbro-
blast, endothelial cells etc.).
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plasma and demonstrated high expression levels of miR-92a leading to
down regulation of the anti-oncogene Dkk-3. Moreover, secretion of
miR-92a–containing EVs by cancer cells into their surrounding en-
vironment facilitated angiogenesis.
It has recently been established that gut microbiota has a signiﬁcant
inﬂuence on the expression pattern of miRNA of intestine cells in-
cluding miRNA packed in EVs. In the Dalmasso and co-authors study
[178], germ-free mice, lacking natural microbiota, were reconstituted
with microbiota from normal special pathogen-free mice leading to the
changes in the miRNA expression proﬁle. It was found that after re-
constitution nine miRNAs were diﬀerentially expressed with four being
upregulated: miR-298, miR-200c, miR-342-p. Among these, miR-200c
was known to be associated with EVs of highly invasive cancer cells
[179–180]. Thus, expression proﬁling of miRNA in EVs may indicate
changes in gut microbiota and a possible predisposition to cancer.
The most remarkable feature of miRNA is its stability in human
bioﬂuids, which allows miRNA molecules to operate outside cell bor-
ders within hostile environments such as intestinal lumen.
3.2. Proteomic studies on gastrointestinal cancer-derived EVs
The underlying mechanisms of protein interactions in EVs and in-
terrelationships between vesicular transport proteins remain to be
studied in GI cancers. To date, some authors have evaluated the role
and function of the proteomic composition of EVs derived from primary
human gastrointestinal cancers and EVs produced by cell lines of gas-
trointestinal origin [139]. Choi and co-authors [181] described how
EVs derived from the HT29 cell line are organized by protein-protein
interactions (PPIs) showing that vesicular transport proteins are inter-
connected via physical interactions and assembled into functional
modules. As a result of the study, 957 of the 1261 vesicular proteins
were mapped onto the extracellular vesicle PPI network, where 304 of
them do not have any PPI in the Human Proteome Reference Database.
Also, it has been shown that actin and actin-binding protein ADP ri-
bosylation factors (ARF), such as ARF1and SRC kinases have the es-
sential signaling role in EV biogenesis [181]. Later studies conﬁrmed
the role of ARFs, such as ARF6 in exosomal biogenesis [182]. Another
study [183] researching serum biomarkers for colorectal cancer me-
tastasis using the secretome approach identiﬁed a total of 910 proteins
from the conditioned media and 145 diﬀerential proteins in SW480 and
SW620 cell lines. The diﬀerential expression pattern of 6 candidate
proteins was validated by Western blot analysis and receiver operating
characteristic curve analysis conﬁrmed that serum trefoil factor 3 and
growth/diﬀerentiation factor 15 could provide a discriminatory diag-
nostic test for predicting colorectal cancer metastasis. Ji and coauthors
[184] found selective enrichment of metastatic factors (MET, S100A8,
S100A9, TNC), lipid raft and lipid-raft associated membrane proteins
(CAV1, FLOT1, FLOT2, PROM1) and some signal transduction mole-
cules (JASG1, SRC, TNIK) in exosomes derived from metastatic SW60
cells. Enrichment of components of Src-signaling pathway in cancer cell
line exosomes identiﬁed by proteomic research [181,183] has recently
been shown by DeRita and colleagues [185].
3.3. Lipids in gastrointestinal cancer-derived EVs
There are a few publications describing a lipid composition of EVs,
perhaps because a methodological approach for studying EV lipids is
complicated and more diﬃcult than this for EV proteomic analysis. EV
membrane lipids have been shown to play an important role in the
modulation of a functional response of target cells, formation, secretion
and internalization of EVs [35,186–189]. Standard approaches include
labeling exosomal and/or other EV subpopulations with ﬂuorescent
lipids [34,190], mass-spectrometry based lipidomics [189,191], and
recently developed lipid-targeting ﬂuorescent peptide probes [192].
Formation of EVs involves enrichment in certain classes of lipids.
Several authors described the enrichment of exosomal fractions
with multiple lipid classes including cholesterol (Ch), sphingolipids,
phosphatidylserine (PS), gangliosides, free fatty acids
[35,188,191,193–194], whereas MPs are enriched in ceramides and
sphingomyelins [191]. Lipid changes happen during diﬀerent steps of EV
biogenesis and aﬀect sorting of EV cargo. For example, some proteins are
sorted by lipid aﬃnity, such as clustering tetraspanins in tetraspanin-en-
riched membrane domains (TEMs) associated with gangliosides and cho-
lesterol. TEMs act as sorting machinery for loading growth factors and
MHC II molecules into exosomes [195] and cholesterol and ceramides
increase exosome release and aﬀect their cargo [186,196].
Exosomes have been shown to contain functional enzymes and
important components of lipid metabolism such as phospholipases,
hydroxycholesterols, prostaglandins and leukotrienes [34,rev.
35,188,197–198]. Bioactive lipids contained by EVs as a part of their
cargo are able to aﬀect the metabolism of target cells (rev. [35]).
To date, the lipidomic characterization of EVs originating from GI
tract cancer is limited to only a few publications describing lipid con-
tent and/or functional activities involving lipid-mediated pathways
induced by exosomes originated from cell lines [150,190,199], while
detailed exploration of their functional and causative role remains
poorly understood. In one of the ground-breaking publications, Ris-
torcelli and co-authors [150] reported that the human pancreatic cell
line SOJ-6 produced lipid raft-enriched exosomes capable of activating
the Notch-1 survival pathway in the cells. To demonstrate the role of
exosomal lipids in promoting cellular death, Beloribi and colleagues
[190] used SOJ-6 cells and exosome-like synthesized nanoparticles
(SELN) composed of lipids typical for lipid rafts. SELN were co-localized
with a marker for lipid rafts ganglioside GM1 and Notch-1 on plasma
membrane or Notch-1 and Rab5a on early endosomes. Furthermore,
Beloribi and co-authors [190] demonstrated a fusion and exchange of
SELN lipids with lipid rafts of plasma membrane and endosomal
membrane and showed that SELN mimicked detrimental eﬀects of
exosomes on the survival of SOJ-6 cells, but not on exosome-insensitive
pancreatic MiaPaCa-2 cells. Exploration of lipids as potential cancer
biomarkers has only recently begun and depends on technological
progress in lipidomic mass-spectrometry. One notable example is the
work of Lydic and co-authors [189], who performed a comprehensive,
in-depth characterization of a “shotgun” lipidomic proﬁling of exo-
somes secreted by LIM 1215 colorectal cell line in comparison with
parental. Using novel sample derivatization techniques, coupled with
high-resolution “shotgun” mass-spectrometry and targeted mass-spec-
trometry, they demonstrated that secreted exosome glyceropho-
spholipid compositions are clearly distinct from parental cells in-
dicating that exosome formation/secretion requires unique partitioning
of particular lipid classes and subclasses. Comparison of exosome versus
cellular lipid proﬁles reveal> 520 individual lipids in 36 lipid classes
and subclasses, as well as substantial lipid remodeling including an
increase of sphingolipids, plasmalogen- and alkyl ether-containing
glycerophospholipids in exosomes. Importantly, obtained lipidomic
results are in broad agreement with publications on exosome content
from other cancer types. A deeper analysis may provide insights on lipid
exosome role in cancer progression. The potential implication of these
studies for diagnostics is yet to be revealed.
4. Circulating EVs in gastrointestinal inﬂammatory disorders and
cancer-derived EVs
A number of studies demonstrated that certain circulating EV frac-
tions are increased in patients with GI cancers, compared to patients
with inﬂammatory gastrointestinal diseases such as Crohn's disease
(CrD) and inﬂammatory bowel disease (IBD) [12,13,104,200–204].
However, the amount of circulating microparticles may be also elevated
in the active phase of gastrointestinal inﬂammatory diseases in com-
parison with healthy controls or cancer patients in remission. Thus,
conducted studies on CrD revealed that the total number of circulating
MPs was signiﬁcantly elevated in CrD patients with active processes
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compared to healthy controls and CrD patients in remission [201,205].
CrD patients in active phases of disease demonstrated an increased total
amount of circulating MPs, particularly pro-coagulant MPs, and MP
fractions originating from platelets, erythrocytes, leukocytes and en-
dothelial cells compared to the patients in remission [201].
These elevated populations of MPs may cooperate in the in-
ﬂammatory process as they induce neutrophil and endothelial activa-
tion, monocyte adhesion and recruitment of various inﬂammatory cells
[201,206–207]. Another study in IBD patients found their levels of
circulating TF+MP to be signiﬁcantly higher than in healthy donors
[202]. Interestingly, higher numbers of circulating total, platelet- and
endothelial-derived MPs were also observed in patients with IBD in
remission as compared to healthy donors supporting the hypothesis of
inﬂammatory cell recruitment [201]. Similar high levels of platelet-
derived MPs were demonstrated in earlier studies on IBD patients with
increased thromboembolism risk [208–210]. Moreover, recently, Mit-
suhashi and co-authors [203] found that intestinal luminal ﬂuid is also
a rich source of proinﬂammatory EVs carrying IL8, IL6, IL10 and TNF
markers. The luminal liquid contains high quantities of EVs of diﬀerent
origin (EVs produced by cells structuring intestinal wall, bacterial outer
membrane vesicles, EVs coming from parasites and food) (Fig. 3).
EV fraction (< 500 nm size) from colonic luminal ﬂuid aspirates
from patients with IBD contained CD63+/CD66b+ (originated from
neutrophils) and CD63+/MUC-1+ (originated from epithelium) sub-
populations, though no statistical signiﬁcance with healthy controls
was found (8.5% vs 10.8% and 39.5% vs 47.4%). EVs of diﬀerent origin
are partly internalized by cell components of intestinal wall, including
cancer cells (illustrated by Fig. 4).
Excess of EVs is released in the circulation. Overall, the increase in
the amount of circulating EVs or circulating annexin V+-EVs [96,211]
has been observed in many cancer types and in inﬂammatory diseases
(rev. [13]), and may not be considered as a speciﬁc diagnostic marker
without additional immunophenotyping, discovering and validating
disease-speciﬁc markers.
5. Analysis of potential biomarkers of gastrointestinal cancers in
EVs
For the last decade EV components have been considered and in-
tensively investigated as potential cancer biomarkers
[66,68,75,80,91,95,169,212]. However, the majority of published stu-
dies report that the expression of biomarkers (or combinations of bio-
markers) is detected only at the advanced metastatic tumor stage, i.e.
when tumors are already detectable by other methods.
Recently, Melo and coauthors [91] described the ﬁrst diagnostic test
based on detecting of a membrane-anchored proteoglycan molecule
glypican-1 (GPC1) on EVs. The authors were able to diﬀerentiate exo-
somes isolated from the blood of patients with benign pancreatic dis-
ease (BPD), from exosomes isolated from the patients with intraductal
papillary mucinous neoplasm (pre-neoplastic lesion) based on the levels
of exosomal GPC1. This non-invasive test, as authors claimed, allowed
them to distinguish patients with pre-cancerous pancreatic lesions, and
to identify patients with late pancreatic cancer (pancreatic ductal
adenocarcinoma, PDAC) with 100% certainty. A comparison of the
GPC1+ exosome-based test with a standard biomarker for pancreatic
cancer (CA-19–9) demonstrated the advantage of using the GPC1+
exosome detection method. The authors analyzed blood from 190 pa-
tients with PDAC and 100 healthy controls, however, only a few pa-
tients with early pre-neoplastic disease. However, there are already new
published results from other group [86] that contradict these ﬁndings.
EVs of diﬀerent origins vary in their stability, but reported serum
EVs and EVs associated with DNA may remain stable between 4 °C and
room temperature for> 24 h [47], which is important for cancer di-
agnostics. Signiﬁcant progress and research interest in circulating
miRNAs and other non-coding RNAs could establish them robust di-
agnostic biomarkers of GI cancers if the feasibility is validated. In the
context of cancer biology, miRNA-based signatures of circulated EVs
could serve as potential biomarkers for clinical use due to their com-
paratively long half-life, high sensitivity and speciﬁcity, relatively easy
accessibility and ability for early cancer detection [213]. A major ad-
vantage of miRNA compared to other RNA types, is in its high stability
compared to longer mRNA transcripts in most biological samples in-
cluding ﬁxed and paraﬃn embedded (FFPE) samples [214–215].
However, during long-term storage their stability may gradually and
diﬀerentially decrease depending on FFPE tissue block age [216].
miRNA stability in circulation is explained by binding to protein and
lipid EV content [217–219].
A number of publications describe microRNA proﬁling in plasma,
serum, and culture supernatants of epithelial cell lines of GI cancers













Bacterial outer membrane vesicles
Fig. 3. Production of EVs in intestinal lumina (intraluminal EVs;
tumor cell-derived-EVs; parasite-derived EVs; bacterial OMVs).
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miR-4644, miR-3976 and miR-4306, were upregulated in 83% of pa-
tients with pancreatic cancer and are considered by the authors [93] to
be promising candidates for screening of pancreatic cancer in larger
patient cohorts. It is important to note that the proﬁle of miRNAs de-
tected in the EVs is signiﬁcantly diﬀerent from that obtained from
plasma samples as was demonstrated with miRNA 20a, miRNA 21,
miRNA 92a, miRNA 106 and others [221]. Despite the existing opti-
mism that miRNA/miRNA signatures may be considered as perspective
biomarkers for colorectal cancer [173,222–224], and other GI tract
cancers and gastrointestinal tract inﬂammatory diseases [225–226],
other reports demonstrated that the majority of detected miRNAs are
not disease speciﬁc [227–228]. Though publications suggesting EV
microRNA signatures for cancer grow exponentially throughout the last
decade, the suitability for clinical applications is still limited due to
absence of endogenous controls to normalize circulating EVs microRNA
levels, and conﬂicting results across the studies.
6. EVs and cancer co-evolution
It is now accepted that solid tumors are likely to derive from the co-
evolution of neoplastic cells, stromal components, vasculature, and
immune cells [229]. As tumors grow in size, an array of molecular
modiﬁcations aggregates, giving rise to multiple cell subpopulations,
each with the ability to proliferate and mutate further. Moreover,
neoplastic cell populations are able to regulate the nature of other types
of cells in their microenvironment, converting their intrinsic anti-tu-
moral response into pro-tumoral activity [230–231]. Therefore, a ma-
lignant tumor is composed not only of neoplastic cells, which are het-
erogeneous in terms of genetic and phenotypic features, but also of
heterogeneous healthy cell populations participating in anti-tumor
immune response and communicating with cells, forming a particular
extracellular matrix that supports cancer evolution and progression
[151]. EVs are critical mediators of intercellular communication and
can orchestrate stroma, tumor microenvironments and tumor hetero-
geneity inﬂuencing the dynamics of disease progression and metastasis
outgrowth [232–234], promoting angiogenesis via Egr-1 activation
[235], down-regulation of VEGF expression [20], microRNA production
[236], and implicating other mechanisms, such as epigenetic regulation
of cancer progression.
Longitudinal studies of cancer patients may reveal possible
mechanisms of tumor heterogeneity/evolution [237]. Thus, Mege and
co-authors [96], compared MPs from patients with CRC, pancreatic
cancer, chronic pancreatitis and IBD, and characterized the distribution
of diﬀerent MP cellular origins (platelet-derived MPs (PMPs), en-
dothelial MPs (EMPs), erythrocyte-derived MPs (EryMPs), leukocyte-
derived MPs (LeuMPs) and MPs expressing of AnV and diﬀerent MP
antigens (tissue factor (TF), mucin1 (MUC1), podoplanin (PODO), etc.).
Besides the diﬀerences between patient groups, authors also found
microparticle signature changes before and after the “composite”
complete remission (CRC), indicating that quantitative and qualitative
changes happen in MP signature during cancer evolution.
Another important aspect of cancer evolution is the epigenetic
regulation of gene transcription that mediates cancer cell fate, pro-
liferation and diﬀerentiation. The initial strategy using aberrant me-
thylation for diagnostics of tumor-speciﬁc hypermethylated genes was
challenging because chronic inﬂammation also induced changes in
methylation levels [238,239]. The search for early markers of pan-
creatic cancer also includes epigenetic markers [240]. Thus, DNA me-
thylation of ADAM metalloproteinase and basonuclin in serum appears
to have prognostic value for pancreatic cancer [241].
However, tumor evolution and EVs modulating eﬀects on GI cancers
are always considered from the point of EVs originating only from
eukaryotic cells, and therefore completely neglects EVs originating
from human microbiota.
7. EVs originated from gastrointestinal cancer and human
microbiota
Gut microbiota play a crucial role in the pathogenesis of mucosal
inﬂammation in GI tract disorders. Bacterial, mycobacterial and viral
infections are found to be important in IBD pathogenesis [242]. Prac-
tically all rodent models of IBD can be mitigated by treatment with
antibiotics or by transferring mice into germ-free conditions [243–244].
In mouse models, colitis-associated cancer did not develop in animals
treated with antibiotics or germ-free environments [245–246].
The microorganisms that are most frequently associated with cancer
development include Mycobacterium avium subspecies paratuberculosis,
adherent enteroinvasive Escherichia coli, Chlamydia pneumoniae and
yeasts, such as Candida albicans and Saccharomyces cerevisiae [247]. The
intestine is normally colonized by approximately 100 trillion
Fig. 4. Internalization of cancer-derived EVs by colorectal cancer cell
line HT29. EVs from plasma of patients with colorectal cancer were
puriﬁed, quantitated, labeled by PKH26 and incubated with color-
ectal cancer cell line HT29 for 18 h at 37 °C. Further cells were
imagined with internalized individual EVs (Arrow) and cluster EVs
(arrow head) using confocal laser scanning microscope ZEISS LSM780
(objective ×63, 540 to 552 nm band pass excitation ﬁlters and 575 to
640 nm band pass emission ﬁlters).
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microorganisms [248] comprising 500–1500 diﬀerent species. Two
major commensal groups in the mammalian intestine include Firmicutes
(gram-positive bacteria) and Bacteroidetes (gram-negative bacteria)
phyla [249–250] forming approximately 90% of the total microbiome.
Bacteroides spp. dominates GI microbiota, representing approximately
30% of all bacteria in GI tract, and is most resistant to antibiotics among
anaerobes [251]. Patients with GI tract cancers have speciﬁc enteric
patterns of microbiome associated with an increase of certain bacterial
species. Thus, stools derived from CRC patients had increased levels of
Enterococcus, Escherichia, Shigella, Klebsiella, Streptococcus, Peptos-
treptococcus, Firmicutes, Fusobacterium and Bacteroidetes [245,252]. Vil-
joen and co-authors [253]evaluated important clinico-pathological
features in Fusobacterium spp. and enterotoxigenic Bacteroides fragilis
(ETBF), concluding that these bacteria were present at signiﬁcantly
higher levels in late-stage CRC patients in comparison with healthy
individuals. Fusobacterium spp. is not carcinogenic, but may lead to
tumorigenesis indirectly by enhancing inﬂammation and stimulating
cancer cell proliferation [254]. Fusobacterium spp. acts by activating
FadA adhesion, which triggers colonic epithelial cells (CEC) Wnt sig-
naling and enhances epithelial cell proliferation. The other important
bacterial species, ETBF, produces the B. fragilis toxin (bft), which is
associated with colorectal cancer, diarrheal disease, etc. [255]. It is
important, however, to emphasize that α- and ε- clades of Proteobacteria
including H.pylori and another pathogen of digestive tract, Campylo-
bacter jejuni, produce altered form of ﬂagellin molecule that is not re-
cognized by Toll-like receptor TLR5, but preserve bacterial motility
[256].
As one of the major mechanisms, bacteria representing gut micro-
biota, release vesicles named outer membrane vesicles (OMVs) for
Gram-negative vesicles, or blebs, for Gram-positive bacteria [257]. For
simplicity we will use the term bacterial MVs or bMVs to refer to both
types of these vesicles. bMVs are 40–300 nm in size, serve as part of the
bacterial secretion and transport system and can deliver their cargo
(DNA and RNA, protein, lipids and other biologically active molecules)
[24,257] to bacterial and/or eukaryotic cells. bMVs are also a rich
source of immunomodulating lipopolysaccharides, lipoproteins, pepti-
doglycans and other bioactive components which are described for
many species of Gram-negative bacteria residing in human gastro-
intestinal tract including Escherichia coli, Helicobacter pylori, Fuso-
bacterium nucleatum, B. fragilis and others [253,258–265]. Recently,
Chu and co-authors [264], demonstrated that bMVs shed by B. fragilis
deliver immunomodulatory molecules such as a capsular poly-
saccharide A (PSA) to intestinal dendritic cells (DC) of mice and acti-
vate a noncanonical autophagy pathway requiring IBD-associated
genes, NOD2 and ATG16L1 for protection from colitis. Consistent with
mouse research data, cells from Crohn's disease patients and healthy
controls respond to puriﬁed PSA and required functional ATG16L1 to
induce CD4+ Foxp3+IL-10+ T-regulatory cells in response to OMVs
from B. fragilis. These bMVs require human ortholog IBD associated
genes ATG16L1 and NOD2 (the later encodes an intracellular sensor of
bacterial peptidoglycan) in order to activate non-canonical autophagy
protection pathway against colitis. Moreover, β-lactamases associated
with bMVs that produced by Bacteroides sp. confer antibiotic resistance
not only to the producing organism but also to other commensal bac-
teria and enteric pathogens (such as Salmonella typhimurium) against β-
lactam antibiotics [266]. The bMVs have also been implicated in the
pathogenesis of gastrointestinal chronic inﬂammatory diseases in-
cluding Crohn's disease [263] and Helicobacter pylori associated in-
ﬂammation [261].
8. Extracellular vesicles, interspecies communication and
molecular mimicry
Gastrointestinal tract is a place where inter-species and even inter-
kingdom communication constantly occurs. EVs derived from host eu-
karyotic cells and from prokaryotic symbiotic and/or pathogenic cells,
edible plants [267], fungi and parasitic EVs produced by helminths
[268] meet in intraluminal space and interact with intestinal cells.
Recently, interspecies communication between nematodes (helminths)
and host intestinal cells was reported by Buck and co-authors [269].
Remarkably, Heligmosomoides polygyrus secrete miRNA-loaded EVs that
are internalized by host mice cells and suppress host immune response.
EV secretion was shown for many human parasites, such as trematodes
(Schistosoma mansoni and Schistosoma japonicum) [270,271] and ne-
matodes (Fasciola hepatica, Teladorsagia circumcincta), and plays an
important role in establishing and maintaining parasitic infection
[272]. Circulating exosomal miRNAs after internalization by target cells
can also act as ligands of Toll-like Receptors (TLRs) [273]. Interestingly,
mice TLRs (TLR13) were reported to recognize conserved nucleic acids
such as 23S ribosomal RNA molecule of bacterial pathogen Staphylo-
coccus aureus [274]. Recent progress has led to identiﬁcation of a large
variety of cytosolic nucleic acid sensors [275]. Further research in this
area oﬀers new scenarios to understand complexity that exists in the
interaction between organisms on inter-species and inter-kingdom le-
vels.
The intestinal EVs represent a huge reservoir of microbial and
parasitic antigens. New evidence demonstrates that bacterial DNA in-
tegration and related mutagenesis through lateral gene transfer may
occur in cancer cells [276,277]. EVs can serve as a hypothetic vehicle
for this transfer, since they carry diﬀerent types of DNA and RNA.
Moreover, protein epitopes can be shared between microbial molecules
and self-antigens, and molecular mimicry can lead to the formation of
cross-reactive antigens and/or activation T-lymphocytes. Target epi-
topes can have only distant homologies with initial antigenic triggers
[278] and epitope spreading can lead to tissue destruction, apoptosis
and concomitant presentation of self- and microbial antigens [279].
Table 4
Proteomic analysis of colorectal cancer-derived EVs [123,281–282] and matching protein sequences in commensal and pathogenic microorganisms of GI tract.
Protein family Protein found in human colorectal EVs proteome Microorganism containing matched protein sequence
Integrins Integrin-α2 precursor;
Integrin-α5-precursor;
Integrins α1, 2, 3, 6; β1, 4
Helicobacter pylori (CagL) interacts with α5β3 and α5β1 integrins
[283–284];
Candida albicans (SAP4, SAP5) [285]
Regulatory proteins (regulation of actin
skeleton)
Tuba-protein Listeria monocytogenes (InIC binds with high aﬃnity to SH3 Tuba domain)
[286])
Keratins 2a, 10, 13, 19, 24, type I, cytoskeletal 9, 14, 18, 19, 20,
type II, cytoskeletal 1, 2, 5, 8
Enterobacteriaceae (serine protease autotransporter pet protein binding to
K8) [287];
Enteropathogenic Escherichia coli (keratin-dependent actin
reorganization) [288];
Salmonella enterica (interaction SspC protein with K8) [289];
Salmonella enterica (interaction SipC protein with K18 [290];
Shigella ﬂexneri (IpaC binding to K18) [291]; Streptococcus agalactiae (Srr
protein binding to K4) [292];
Streptococcus parasanguinis [293–294]
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Microbial commensals can induce cross-reactive lymphocytes (rev.
[279]) and antibody responses in the gut can be directed against
commensal and self-antigens cases being polyreactive in up to 25%
[280].
We hypothesized that colorectal cancer proteomes derived from EVs
released by GI tract cancer cells may have protein sequences matching
gut microbiome organisms. To investigate this, we re-analyzed the
colorectal EV proteome studied by the Choi group [123,281,282] and
compared it with protein sequences from diﬀerent commensal bacteria
and viruses. As a result, a number of matching microbial sequences was
identiﬁed (please, see Table 4 for detailed analysis results).
Furthermore, as shown in Fig. 5, we identiﬁed the pseudokinase
domain in the B. fragilis genome with sequence matching platelet-de-
rived growth factor receptor alpha (PDGFR-α). Mutations of PDGF/
PDGFRs genes, particularly in kinase and juxtamembrane domain [295-
297] can lead to an increased PDGFR signaling and is notably asso-
ciated with the stage, grade and poor outcomes of various cancers in-
cluding colorectal cancers [298,299]. Interestingly, while orthologs in
Mycobacterium tuberculosis possess the characteristic catalytic residue
(aspartate), this residue and segment of 16 amino acids is absent in
Bacteroides spp., so this protein is predicted to be catalytically inactive,
but functional pseudokinase [300]. The loss of catalytic activity is
mirrored by the acquisition of a potential activation loop (Fig. 5). We
hypothesize that the presence of this pseudokinase with activation loop
Fig. 5. (A) Multiple sequence alignment for
three kinase domains from Human,
Mycobacterium tuberculosis, and Bacteroides
fragilis, respectively. Left part shows multiple
sequence alignment of three kinase domains
P16234 (591–983), P9WI79 (13–295), and
A0A017PLZ0 (1–295) from Human,
Mycobacterium tuberculosis, and Bacteroides
fragilis, respectively. Here P16234 is Platelet-
derived growth factor receptor alpha (PDGFR-
alpha), whereas P9WI79 and A0A017PLZ0 are
Serine/threonine-protein kinase (PknD); (B)
Superposition of the kinase domains from
Human (represented in thin ribbon) and B. fra-
gilis (represented in thick cartoon). Residues that
are critical for kinase activity are shown red in
the multiple sequence alignment. For Human
andMycobacterium tuberculosis, we show G-rich
loop in cyan and activation loop in purple;
whereas for Bacteroides fragilis, G-rich loop is
shown in green and activation loop in yellow
(detailed description in Suppl. File 1). From the
Fig. 4, the PknD from B. fragilis lost the most
part of G-rich loop, as well as sequences diﬀer
largely at activation loop. Since G-rich loop is
critical for ATP-binding, PknD from B. fragilis
could lose the kinase activity and become a pseudo-kinase. (Methods are provided in Suppl. File 1).
Patients with pre-malignant (2)
or benign (3)  tumor






( EVs flow and imaging
cytometry)
Fig. 6. Scheme of identiﬁcation of new biomarkers highly expressed in EVs. (1) EVs puriﬁcation; (2) proteomic analysis; (3) identiﬁcation of hypothetic biomarkers; (4) analysis and
validation of hypothetic biomarkers by ﬂow and imaging ﬂow cytometry.
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and homology to PDGFR-α in Bacteroides spp. may be related to PDGFR-
α role in colorectal carcinogenesis.
This novel approach, (i.e. matching protein sequences from eu-
karyotic EV proteome with the known protein sequences of microbiome
gut bacteria) (as well as the opposite – matching bMVs proteome with
eukaryotic sequences) helps to identify new similarities between bac-
teria and eukaryotic proteins and understand their functional role.
9. Conclusions and future perspectives
Actively secreted EVs from eukaryotic cells as well as from diﬀerent
microbial, fungi, parasitic species and edible plants in GI tract act as
mediators of intracellular and inter-species communication, promote
angiogenesis, induce immune suppression, and facilitate tumor cell
survival and multi-drug resistance. There is a general consensus that the
speciﬁc biosignatures of multiple EV biomarkers will be required for
diagnostics of GI tract cancers. However, this suggestion recently got
challenged when Melo and co-authors developed a simple one-molecule
EV-based test for pancreatic cancer [92]. This study was based on the
search for proteomic markers highly expressed in EVs originating from
patients with advanced tumors and have been identiﬁed in early stages
of GI tumors. A similar approach can lead to the development of EV-
based early diagnosis of diﬀerent GI cancers, such as CRC (Fig. 6).
The power of EVs is related to their unique protein, RNA, miRNA
and DNA proﬁles, ubiquitous distribution (plasma, saliva, gastric juice,
intestinal luminal liquid etc.) and their eﬃcient binding and transfer to
target cells [301]. Many eﬀorts have been devoted to EV proteome
characterization and protein marker discovery [302,303]. We devel-
oped a new approach, consisting of matching protein sequences from
eukaryotic EV proteome with known protein sequences to microbiome
of gut bacteria as well as matching bMVs proteome with eukaryotic
counterparts. We believe that using this strategy, it is possible to
identify potential molecular mimicry protein sequences and these
ﬁndings could be useful for further experimental research of their
functional role.
The current challenges in using EV as clinical biomarkers and in
researching GI tract cancers include analytical variability of diﬀerent
instruments used for EV detection and variability of sample prepara-
tion. The future perspective is the possibility of applying genome
editing tools to engineer EVs loaded with “tailored” cargoes. Despite
thorough EV research, there is much remaining to be studied to un-
derstand the contribution of EVs in GI cancers' pathogenesis and de-
velopment. Overall, the development of the EV ﬁeld has the potential
for early-stage cancer diagnosis, tracking chemo-resistance and ther-
apeutic eﬃcacy, and tailor-made treatment strategies for GI cancer
patients.
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